ArticleResearch square2024
Programable Albumin-Hitchhiking Nanobodies Enhance the Delivery of STING Agonists to Potentiate Cancer Immunotherapy.
John Wilson, Blaise Kimmel, Karan Arora, Neil Chada, Vijaya Bharti, Alexander Kwiatkowski, Jonah Finklestein, Ann Hanna, Emily Arner, Taylor Sheehy and 15 more
Abstract readPreprint
In one paragraphArticle in Research square, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
5 · Who and what moneyAuthors and funding
25 authors.
Blaise KimmelVanderbilt University.
Karan AroraVanderbilt University.
Vijaya BhartiVanderbilt University.
Alexander KwiatkowskiVanderbilt University.
Jonah FinklesteinVanderbilt University.
Ann HannaVanderbilt University Medical Center.
Taylor SheehyVanderbilt University.
Lucinda PastoraVanderbilt University.
Jinming YangVanderbilt University Medical Center.
Payton StoneVanderbilt University.
Lauren HubertVanderbilt University.
Kathern Gibson-CorleyVanderbilt University Medical Center.
Ann RichmondVanderbilt University Medical Center.
Wendy RathmellVanderbilt University Medical Center.
Barbara FingletonVanderbilt University Medical Center.
Funding
Tumor Immunology and Microenvironment Research ProgramP30CA068485 · NCI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI MATTHEW J TYSKA · 1995 to 2026
$172.8MTISSUE CoreP50CA098131 · NCI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI PARK, BEN HO, PIETENPOL, JENNIFER A · 2003 to 2024
$48.7MMEDICAL SCIENTIST TRAINING PROGRAMT32GM007347 · NIGMS · VANDERBILT UNIVERSITY · PI WILLIAMS, CHRISTOPHER S. · 1985 to 2023
$26.3MMULTIDISCIPLINARY BASIC RESEARCH TRAINING IN CANCERT32CA009592 · NCI · VANDERBILT UNIVERSITY · PI Justin M Balko, Julie A Rhoades (Sterling) · 1987 to 2026
$10.4MChemistry-Biology Interface Training GrantT32GM065086 · NIGMS · VANDERBILT UNIVERSITY · PI BACHMANN, BRIAN O, SULIKOWSKI, GARY ALLEN · 2002 to 2022
$7.0MTargeting the NF-kappaB Pathway in MelanomaR01CA116021 · NCI · VANDERBILT UNIVERSITY · PI RICHMOND, ANN, YAN, CHI · 2005 to 2024
$6.7MMedical Scientist Training ProgramT32GM152284 · NIGMS · VANDERBILT UNIVERSITY · PI Christopher S. Williams · 2024 to 2026
$4.8MMetabolic Barriers to T Cell Activation in Clear Cell Renal Cell CarcinomaR01CA217987 · NCI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI Jeffrey C Rathmell · 2018 to 2026
$4.3MIntegrated Training in Engineering and DiabetesT32DK101003 · NIDDK · VANDERBILT UNIVERSITY · PI Jamey D. Young · 2014 to 2026
$3.9MToward Translation of an Immunotherapeutic Nanomedicine for NeuroblastomaR01CA274675 · NCI · VANDERBILT UNIVERSITY · PI John Tanner Wilson · 2022 to 2026
$2.5MEngineered Vaccines for Neoantigen Targeted Cancer ImmunotherapyR01CA266767 · NCI · VANDERBILT UNIVERSITY · PI John Tanner Wilson · 2022 to 2026
$2.4MExpanding the Therapeutic Window of Nanoparticle STING Agonists for Cancer ImmunotherapyR01CA245134 · NCI · VANDERBILT UNIVERSITY · PI WILSON, JOHN TANNER · 2020 to 2025
$1.8MBLRD VA I01 BX002301BLRD VA IK6 BX005225NCI NIH HHS F99 CA253718NCI NIH HHS K00 CA253718NCI NIH HHS P30 CA068485NCI NIH HHS P50 CA098131NCI NIH HHS R01 CA116021NCI NIH HHS R01 CA217987NCI NIH HHS R01 CA245134NCI NIH HHS R01 CA266767NCI NIH HHS R01 CA274675NCI NIH HHS T32 CA009592NIDDK NIH HHS T32 DK101003NIGMS NIH HHS T32 GM007347NIGMS NIH HHS T32 GM065086NIGMS NIH HHS T32 GM152284
6 · The paper itselfAbstract
Stimulator of interferon genes (STING) is a promising target for potentiating antitumor immunity, but multiple pharmacological barriers limit the clinical utility, efficacy, and/or safety of STING agonists. Here we describe a modular platform for systemic administration of STING agonists based on nanobodies engineered for
Indexed as
adoptive T cell transferalbumincancerimmune checkpoint blockadeimmunotherapynanobodySTING
Identifiers
PMID38766114
PMCPMC11100900
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390